374 related articles for article (PubMed ID: 27372731)
1. Chimeric antigen receptors: driving immunology towards synthetic biology.
Sadelain M
Curr Opin Immunol; 2016 Aug; 41():68-76. PubMed ID: 27372731
[TBL] [Abstract][Full Text] [Related]
2. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
[TBL] [Abstract][Full Text] [Related]
3. The basic principles of chimeric antigen receptor design.
Sadelain M; Brentjens R; Rivière I
Cancer Discov; 2013 Apr; 3(4):388-98. PubMed ID: 23550147
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cell Therapy in Hematology.
Ataca P; Arslan Ö
Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
6. Overcoming the toxicity hurdles of genetically targeted T cells.
Casucci M; Hawkins RE; Dotti G; Bondanza A
Cancer Immunol Immunother; 2015 Jan; 64(1):123-30. PubMed ID: 25488419
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.
Condomines M; Arnason J; Benjamin R; Gunset G; Plotkin J; Sadelain M
PLoS One; 2015; 10(6):e0130518. PubMed ID: 26110267
[TBL] [Abstract][Full Text] [Related]
8. The pharmacology of second-generation chimeric antigen receptors.
van der Stegen SJ; Hamieh M; Sadelain M
Nat Rev Drug Discov; 2015 Jul; 14(7):499-509. PubMed ID: 26129802
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
Hombach A; Hombach AA; Abken H
Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
[TBL] [Abstract][Full Text] [Related]
10. Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers.
Majzner RG; Heitzeneder S; Mackall CL
Cancer Cell; 2017 Apr; 31(4):476-485. PubMed ID: 28366678
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy.
Temme A; Schmitz M
Immunotherapy; 2016 Sep; 8(9):983-6. PubMed ID: 27485071
[No Abstract] [Full Text] [Related]
12. [Novel therapy for malignant lymphoma: adoptive immuno-gene therapy using chimeric antigen receptor(CAR)-expressing T lymphocytes].
Ozawa K
Nihon Rinsho; 2014 Mar; 72(3):547-52. PubMed ID: 24724418
[TBL] [Abstract][Full Text] [Related]
13. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
Chmielewski M; Kopecky C; Hombach AA; Abken H
Cancer Res; 2011 Sep; 71(17):5697-706. PubMed ID: 21742772
[TBL] [Abstract][Full Text] [Related]
14. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer.
Melenhorst JJ; Lacey SF; Bedoya F
Curr Drug Targets; 2017; 18(3):332-340. PubMed ID: 26302796
[TBL] [Abstract][Full Text] [Related]
16. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Jamnani FR; Moghimi SM
Cancer Lett; 2013 Jul; 334(2):237-44. PubMed ID: 22902507
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.
Roybal KT; Lim WA
Annu Rev Immunol; 2017 Apr; 35():229-253. PubMed ID: 28446063
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor-modified T cells strike back.
Frigault MJ; Maus MV
Int Immunol; 2016 Jul; 28(7):355-63. PubMed ID: 27021308
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
20. Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers.
Tay JC; Zha S; Wang S
Immunotherapy; 2017 Dec; 9(16):1339-1349. PubMed ID: 29185393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
